Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 1186 · Lower Drug Costs for Families Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1395w–3a Use of average sales price payment methodology

+18 −16Shown
More for 42 U.S.C. § 1395w–3a
Read § 1395w–3aOnly this section
10 changes the bill asks for here, 10 carried out
  1. Carried out:

    in paragraph (1)(A)(i), by striking units and inserting billing units;

  2. Carried out:

    in paragraph (2)(A), by striking for which payment is made under this part and inserting that would be payable under this part if such drug were furnished to an individual enrolled under this part; and

  3. Carried out:

    in subparagraph (A)(i), by striking units and inserting billing units; and

  4. Carried out:

    by striking subparagraph (B) and inserting the following:(B) Total number of billing units.— For purposes of subparagraph (A)(i), the total number of billing units with respect to a part B rebatable drug is determined as follows: (i) Determine the total number of units equal to— (I) the total number of units, as reported under …

  5. Carried out:

    in subparagraph (D), by striking July 1, 2021 and inserting July 1, 2016; and

  6. Carried out:

    in subparagraph (E), by striking January 2021 and inserting January 2016; and

  7. Carried out:

    by striking December 1, 2020 and inserting December 31, 2015; and

  8. Carried out:

    by striking January 2021 and inserting January 2016;

  9. Carried out:

    in subparagraph (B), by striking December 1, 2020 and inserting December 31, 2015; and

  10. Carried out:

    in subparagraph (C), by striking January 2021 and inserting January 2016.

§ 1395w–3a(i)Rebate by manufacturers for single source drugs and biologicals with prices increasing faster than inflation(1)–(2)

Start of § 1395w–3a to (i)(1) unchanged ·

(A) Secretarial provision of information Not later than 6 months after the end of each calendar quarter beginning on or after January 1, 2023, the Secretary shall, for each part B rebatable drug, report to each manufacturer of such part B rebatable drug the following for such calendar quarter:

(i) Information on the total number of [inserted: billing ]units of the billing and payment code described in subparagraph (A)(i) of paragraph (3) with respect to such drug and calendar quarter.

(ii) Information on the amount (if any) of the excess average sales price increase described in subparagraph (A)(ii) of such paragraph for such drug and calendar quarter.

(iii) The rebate amount specified under such paragraph for such part B rebatable drug and calendar quarter.

(B) Manufacturer requirement For each calendar quarter beginning on or after January 1, 2023, the manufacturer of a part B rebatable drug shall, for such drug, not later than 30 days after the date of receipt from the Secretary of the information described in subparagraph (A) for such calendar quarter, provide to the Secretary a rebate that is equal to the amount specified in paragraph (3) for such drug for such calendar quarter.

(C) Transition rule for reporting The Secretary may, for each part B rebatable drug, delay the timeframe for reporting the information described in subparagraph (A) for calendar quarters beginning in 2023 and 2024 until not later than September 30, 2025.

(2) Part B rebatable drug defined

(A) In general In this subsection, the term “part B rebatable drug” means a single source drug or biological (as defined in subparagraph (D) of subsection (c)(6)), including a biosimilar biological product (as defined in subparagraph (H) of such subsection) but excluding a qualifying biosimilar biological product (as defined in subsection (b)(8)(B)(iii)), [struck: for][inserted: that] [struck: which][inserted: would] [struck: payment][inserted: be] [struck: is][inserted: payable] [struck: made][inserted: under] [inserted: this part if such drug were furnished to an individual enrolled ]under this part, except such term shall not include such a drug or biological—

(i) if, as determined by the Secretary, the average total allowed charges for such drug or biological under this part for a year per individual that uses such a drug or biological are less than, subject to subparagraph (B), $100; or

(ii) that is a vaccine described in subparagraph (A) or (B) of section 1395x(s)(10) of this title.

§ 1395w–3a(i)Rebate by manufacturers for single source drugs and biologicals with prices increasing faster than inflation(3)–(5)

(i)(2)(B)–(3) unchanged ·

(A) In general For purposes of paragraph (1), the amount specified in this paragraph for a part B rebatable drug assigned to a billing and payment code for a calendar quarter is, subject to subparagraphs (B) and (G) and paragraph (4), the estimated amount equal to the product of—

(i) the total number of [inserted: billing ]units determined under subparagraph (B) for the billing and payment code of such drug; and

(ii) the amount (if any) by which—

(I) the amount equal to—

(aa) in the case of a part B rebatable drug described in paragraph (1)(B) of subsection (b), 106 percent of the amount determined under paragraph (4) of such section2 for such drug during the calendar quarter; or

(bb) in the case of a part B rebatable drug described in paragraph (1)(C) of such subsection, the payment amount under such paragraph for such drug during the calendar quarter; exceeds

(II) the inflation-adjusted payment amount determined under subparagraph (C) for such part B rebatable drug during the calendar quarter.

(B) Total number of [inserted: billing ]units[inserted: .—] For purposes of subparagraph (A)(i), the total number of [struck: units for the ]billing [struck: and][inserted: units] [struck: payment code ]with respect to a part B rebatable drug [struck: furnished during a calendar quarter described in subparagraph (A) ]is [struck: equal][inserted: determined] [struck: to—][inserted: as follows:]

(i) [inserted: Determine the total number of units equal to—]

(I) [inserted: the total number of units, as reported under subsection (c)(1)(B) for each National Drug Code of such drug during the calendar quarter that is two calendar quarters prior to the calendar quarter as described in subparagraph (A), minus]

(II) [inserted: the total number of units with respect to each National Drug Code of such drug for which payment was made under a State plan under title XIX (or waiver of such plan), as reported by States under section 1927(b)(2)(A) for the rebate period that is the same calendar quarter as described in subclause (I).]

[struck: the number of units for the billing and payment code of such drug furnished during such calendar quarter, minus]

(ii) [inserted: Convert the units determined under clause (i) to billing units for the billing and payment code of such drug, using a methodology similar to the methodology used under this section, by dividing the units determined under clause (i) for each National Drug Code of such drug by the billing unit for the billing and payment code of such drug.]

(iii) [inserted: Compute the sum of the billing units for each National Drug Code of such drug in clause (ii).]

[struck: the number of units for such billing and payment code of such drug furnished during such calendar quarter—]

[struck: (I)] [struck: with respect to which the manufacturer provides a discount under the program under section 256b of this title or a rebate under section 1396r–8 of this title; or]

[struck: (II)] [struck: that are packaged into the payment amount for an item or service and are not separately payable.]

(C) Determination of inflation-adjusted payment amount The inflation-adjusted payment amount determined under this subparagraph for a part B rebatable drug for a calendar quarter is—

(i) the payment amount for the billing and payment code for such drug in the payment amount benchmark quarter (as defined in subparagraph (D)); increased by

(ii) the percentage by which the rebate period CPI–U (as defined in subparagraph (F)) for the calendar quarter exceeds the benchmark period CPI–U (as defined in subparagraph (E)).

(D) Payment amount benchmark quarter The term “payment amount benchmark quarter” means the calendar quarter beginning July 1, [struck: 2021][inserted: 2016].

(E) Benchmark period CPI–U The term “benchmark period CPI–U” means the consumer price index for all urban consumers (United States city average) for January [struck: 2021][inserted: 2016].

(F) Rebate period CPI–U The term “rebate period CPI–U” means, with respect to a calendar quarter described in subparagraph (C), the greater of the benchmark period CPI–U and the consumer price index for all urban consumers (United States city average) for the first month of the calendar quarter that is two calendar quarters prior to such described calendar quarter.

(G) Reduction or waiver for shortages and severe supply chain disruptions The Secretary shall reduce or waive the amount under subparagraph (A) with respect to a part B rebatable drug and a calendar quarter—

(i) in the case of a part B rebatable drug that is described as currently in shortage on the shortage list in effect under section 356e of title 21 at any point during the calendar quarter; or

(ii) in the case of a biosimilar biological product, when the Secretary determines there is a severe supply chain disruption during the calendar quarter, such as that caused by a natural disaster or other unique or unexpected event.

(4) Special treatment of certain drugs and exemption

(A) Subsequently approved drugs In the case of a part B rebatable drug first approved or licensed by the Food and Drug Administration after December [struck: 1][inserted: 31], [struck: 2020][inserted: 2015], clause (i) of paragraph (3)(C) shall be applied as if the term “payment amount benchmark quarter” were defined under paragraph (3)(D) as the third full calendar quarter after the day on which the drug was first marketed and clause (ii) of paragraph (3)(C) shall be applied as if the term “benchmark period CPI–U” were defined under paragraph (3)(E) as if the reference to “January [struck: 2021][inserted: 2016]” under such paragraph were a reference to “the first month of the first full calendar quarter after the day on which the drug was first marketed”.

(B) Timeline for provision of rebates for subsequently approved drugs In the case of a part B rebatable drug first approved or licensed by the Food and Drug Administration after December [struck: 1][inserted: 31], [struck: 2020][inserted: 2015], paragraph (1)(B) shall be applied as if the reference to “January 1, 2023” under such paragraph were a reference to “the later of the 6th full calendar quarter after the day on which the drug was first marketed or January 1, 2023”.

(C) Selected drugs In the case of a part B rebatable drug that is a selected drug (as defined in section 1320f–1(c) of this title) with respect to a price applicability period (as defined in section 1320f(b)(2) of this title), in the case such drug is no longer considered to be a selected drug under section 1320f–1(c) of this title, for each applicable period (as defined under subsection (g)(7)) beginning after the price applicability period with respect to such drug, clause (i) of paragraph (3)(C) shall be applied as if the term “payment amount benchmark quarter” were defined under paragraph (3)(D) as the calendar quarter beginning January 1 of the last year during such price applicability period with respect to such selected drug and clause (ii) of paragraph (3)(C) shall be applied as if the term “benchmark period CPI–U” were defined under paragraph (3)(E) as if the reference to “January [struck: 2021][inserted: 2016]” under such paragraph were a reference to “the July of the year preceding such last year”.

(5) Application to beneficiary coinsurance In the case of a part B rebatable drug furnished on or after April 1, 2023, if the payment amount described in paragraph (3)(A)(ii)(I) (or, in the case of a part B rebatable drug that is a selected drug (as defined in section 1320f–1(c) of this title), the payment amount described in subsection (b)(1)(B) for such drug) for a calendar quarter exceeds the inflation adjusted payment for such quarter—

(A) in computing the amount of any coinsurance applicable under this part to an individual to whom such drug is furnished, the computation of such coinsurance shall be equal to 20 percent of the inflation-adjusted payment amount determined under paragraph (3)(C) for such part B rebatable drug; and

Rest of § 1395w–3a unchanged ·

42 U.S.C. § 1395w–114b Manufacturer rebate for certain drugs with prices increasing faster than inflation

+14 −148 of 10 shown
More for 42 U.S.C. § 1395w–114b
Read § 1395w–114bOnly this section
10 changes the bill asks for here, 8 carried out
  1. Not carried out:

    in subparagraph (A)(i), by striking the total number of units and all that follows through the semicolon and inserting the following: the total number of units that are used to calculate the average manufacturer price of such dosage form and strength with respect to such part D rebatable drug, as reported by the manufacturer of such drug under section 1927 for each month, with respect to such period;; and

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: striking QTEXT and all that follows through the semicolon and inserting the following: QTEXT; and
  2. Carried out:

    by striking subparagraph (B) and inserting the following:(B) Excluded units.— For purposes of subparagraph (A)(i), the Secretary shall exclude from the total number of units for a dosage form and strength with respect to a part D rebatable drug, with respect to an applicable period, the following: (i) Units of each dosage form and …

  3. Not carried out:

    in paragraph (6), by striking information.—The Secretary and all that follows through rebatable covered part D drug dispensed and inserting the following: AMP reports.—The Secretary shall provide for a method and process under which, in the case of a manufacturer of a part D rebatable drug that submits revisions to information submitted under section 1927 by the manufacturer with respect to such drug; and

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: striking QTEXT and all that follows through QTEXT and inserting the following: QTEXT; and
  4. Carried out:

    by striking subsection (d) and inserting the following:(d) Information.— For purposes of carrying out this section, the Secretary shall use information submitted by manufacturers under section 1927(b)(3) and information submitted by States under section 1927(b)(2)(A)..

  5. Carried out:

    by striking October 1, 2021 and inserting October 1, 2016; and

  6. Carried out:

    by striking January 2021 and inserting January 2016; and

  7. Carried out:

    in subparagraph (C), by striking January 2021 and inserting January 2016; and

  8. Carried out:

    by striking January 1, 2021 and inserting January 1, 2016; and

  9. Carried out:

    by striking October 1, 2021 and inserting October 1, 2016; and

  10. Carried out:

    in paragraph (4), by striking January 2021 and inserting January 2016.

§ 1395w–114b(b)(1)In general(A)–(C)

Start of § 1395w–114b to (b)(1)(A)(ii) unchanged ·

(I) the annual manufacturer price (as determined in paragraph (2)) paid for such dosage form and strength with respect to such part D rebatable drug for the period; exceeds

(II) the inflation-adjusted payment amount determined under paragraph (3) for such dosage form and strength with respect to such part D rebatable drug for the period.

(B) Excluded units[inserted: .—] [inserted: For purposes of subparagraph (A)(i), the Secretary shall exclude from the total number of units for a dosage form and strength with respect to a part D rebatable drug, with respect to an applicable period, the following:]

(i) [inserted: Units of each dosage form and strength of such part D rebatable drug for which payment was made under a State plan under title XIX (or waiver of such plan), as reported by States under section 1927(b)(2)(A).]

(ii) [inserted: Units of each dosage form and strength of such part D rebatable drug for which a rebate is paid under section 1847A(i).]

(iii) [inserted: Beginning with plan year 2026, units of each dosage form and strength of such part D rebatable drug for which the manufacturer provides a discount under the program under section 340B of the Public Health Service Act.]

[struck: For purposes of subparagraph (A)(i), beginning with plan year 2026, the Secretary shall exclude from the total number of units for a dosage form and strength with respect to a part D rebatable drug, with respect to an applicable period, units of each dosage form and strength of such part D rebatable drug for which the manufacturer provides a discount under the program under section 256b of this title.]

(C) Reduction or waiver for shortages and severe supply chain disruptions The Secretary shall reduce or waive the amount under subparagraph (A) with respect to a part D rebatable drug and an applicable period—

(i) in the case of a part D rebatable drug that is described as currently in shortage on the shortage list in effect under section 356e of title 21 at any point during the applicable period;

§ 1395w–114b(b)–(f)

(b)(1)(C)(ii)–(4)(B)(i) unchanged ·

(ii) the total number of units reported under section 1396r–8 of this title of such dosage form and strength with respect to such payment amount benchmark period.

(5) Special treatment of certain drugs and exemption

(A) Subsequently approved drugs In the case of a part D rebatable drug first approved or licensed by the Food and Drug Administration after October 1, [struck: 2021][inserted: 2016], subparagraphs (A) and (B) of paragraph (4) shall be applied as if the term “payment amount benchmark period” were defined under subsection (g)(3) as the first calendar year beginning after the day on which the drug was first marketed and subparagraph (B) of paragraph (3) shall be applied as if the term “benchmark period CPI–U” were defined under subsection (g)(4) as if the reference to “January [struck: 2021][inserted: 2016]” under such subsection were a reference to “January of the first year beginning after the date on which the drug was first marketed”.

(B) Treatment of new formulations

(i) In general In the case of a part D rebatable drug that is a line extension of a part D rebatable drug that is an oral solid dosage form, the Secretary shall establish a formula for determining the rebate amount under paragraph (1) and the inflation adjusted payment amount under paragraph (3) with respect to such part D rebatable drug and an applicable period, consistent with the formula applied under subsection (c)(2)(C) of section 1396r–8 of this title for determining a rebate obligation for a rebate period under such section.

(ii) Line extension defined In this subparagraph, the term “line extension” means, with respect to a part D rebatable drug, a new formulation of the drug, such as an extended release formulation, but does not include an abuse-deterrent formulation of the drug (as determined by the Secretary), regardless of whether such abuse-deterrent formulation is an extended release formulation.

(C) Selected drugs In the case of a part D rebatable drug that is a selected drug (as defined in section 1320f–1(c) of this title) with respect to a price applicability period (as defined in section 1320f(b)(2) of this title), in the case such drug is no longer considered to be a selected drug under section 1320f–1(c) of this title, for each applicable period (as defined under subsection (g)(7)) beginning after the price applicability period with respect to such drug, subparagraphs (A) and (B) of paragraph (4) shall be applied as if the term “payment amount benchmark period” were defined under subsection (g)(3) as the last year beginning during such price applicability period with respect to such selected drug and subparagraph (B) of paragraph (3) shall be applied as if the term “benchmark period CPI–U” were defined under subsection (g)(4) as if the reference to “January [struck: 2021][inserted: 2016]” under such subsection were a reference to “January of the last year beginning during such price applicability period with respect to such drug”.

(6) Reconciliation in case of revised information The Secretary shall provide for a method and process under which, in the case where a PDP sponsor of a prescription drug plan or an MA organization offering an MA–PD plan submits revisions to the number of units of a rebatable covered part D drug dispensed, the Secretary determines, pursuant to such revisions, adjustments, if any, to the calculation of the amount specified in this subsection for a dosage form and strength with respect to such part D rebatable drug and an applicable period and reconciles any overpayments or underpayments in amounts paid as rebates under this subsection. Any identified underpayment shall be rectified by the manufacturer not later than 30 days after the date of receipt from the Secretary of information on such underpayment.

(c) Rebate deposits Amounts paid as rebates under subsection (b) shall be deposited into the Medicare Prescription Drug Account in the Federal Supplementary Medical Insurance Trust Fund established under section 1395t of this title.

(d) Information[inserted: .—] [inserted: For purposes of carrying out this section, the Secretary shall use information submitted by manufacturers under section 1927(b)(3) and information submitted by States under section 1927(b)(2)(A).]

[struck: For purposes of carrying out this section, the Secretary shall use information submitted by—]

[struck: (1)] [struck: manufacturers under section 1396r–8(b)(3) of this title;]

[struck: (2)] [struck: States under section 1396r–8(b)(2)(A) of this title; and]

[struck: (3)] [struck: PDP sponsors of prescription drug plans and MA organization offering MA–PD plans under this part.]

(e) Civil money penalty If a manufacturer of a part D rebatable drug has failed to comply with the requirement under subsection (a)(2) with respect to such drug for an applicable period, the manufacturer shall be subject to a civil money penalty in an amount equal to 125 percent of the amount specified in subsection (b) for such drug for such period. The provisions of section 1320a–7a of this title (other than subsections (a) (with respect to amounts of penalties or additional assessments) and (b)) shall apply to a civil money penalty under this subsection in the same manner as such provisions apply to a penalty or proceeding under section 1320a–7a(a) of this title.

(f) Limitation on administrative or judicial review There shall be no administrative or judicial review of any of the following:

§ 1395w–114b(g)Definitions(2)–(6)

(f)(1)–(g)(1) unchanged ·

(2) Unit The term “unit” means, with respect to a part D rebatable drug, the lowest dispensable amount (such as a capsule or tablet, milligram of molecules, or grams) of the part D rebatable drug, as reported under section 1396r–8 of this title.

(3) Payment amount benchmark period The term “payment amount benchmark period” means the period beginning January 1, [struck: 2021][inserted: 2016], and ending in the month immediately prior to October 1, [struck: 2021][inserted: 2016].

(4) Benchmark period CPI–U The term “benchmark period CPI–U” means the consumer price index for all urban consumers (United States city average) for January [struck: 2021][inserted: 2016].

(5) Applicable period CPI–U The term “applicable period CPI–U” means, with respect to an applicable period, the consumer price index for all urban consumers (United States city average) for the first month of such applicable period.

(6) Average manufacturer price The term “average manufacturer price” has the meaning, with respect to a part D rebatable drug of a manufacturer, given such term in section 1396r–8(k)(1) of this title, with respect to a covered outpatient drug of a manufacturer for a rebate period under section 1396r–8 of this title.

Rest of § 1395w–114b unchanged ·

Step through the changes